Quarterly ResultMay 7, 2026, 05:01 PM
Apyx Medical Q1 Sales +32% to $12.49M; Net Loss Halved to $2.11M
AI Summary
Apyx Medical Corp reported a significant improvement in its first-quarter 2026 financial results, with net sales increasing by 32% to $12.49 million and net loss attributable to stockholders nearly halving to $2.11 million from $4.15 million in the prior year. The company also submitted a 510(k) premarket notification to the FDA for label expansion of its AYON Body Contouring System to include power liposuction, with clearance anticipated in Q2 2026. Apyx believes the increasing use of GLP-1 drugs, while initially impacting revenue, could eventually drive demand for its Renuvion products due to associated loose skin.
Key Highlights
- Net sales increased 32.45% to $12.49 million for Q1 2026.
- Net loss attributable to stockholders decreased 49.2% to $2.11 million.
- Loss per share improved to $(0.05) from $(0.10) year-over-year.
- Surgical Aesthetics segment sales rose 36.1% to $10.73 million.
- OEM segment sales increased 13.8% to $1.76 million.
- International sales grew to 35.1% of total revenues for Q1 2026.
- Submitted 510(k) to FDA for AYON Body Contouring System label expansion.
- Net cash used in operating activities decreased to $(0.57) million.
Price Impact
More from APYX